126 related articles for article (PubMed ID: 38103202)
21. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
[TBL] [Abstract][Full Text] [Related]
22. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
[TBL] [Abstract][Full Text] [Related]
23. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
24. Virological characteristics of the SARS-CoV-2 BA.2.86 variant.
Tamura T; Mizuma K; Nasser H; Deguchi S; Padilla-Blanco M; Oda Y; Uriu K; Tolentino JEM; Tsujino S; Suzuki R; Kojima I; Nao N; Shimizu R; Wang L; Tsuda M; Jonathan M; Kosugi Y; Guo Z; Hinay AA; Putri O; Kim Y; Tanaka YL; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; ; Saito A; Ito J; Irie T; Tanaka S; Zahradnik J; Ikeda T; Takayama K; Matsuno K; Fukuhara T; Sato K
Cell Host Microbe; 2024 Feb; 32(2):170-180.e12. PubMed ID: 38280382
[TBL] [Abstract][Full Text] [Related]
25. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
Ao D; He X; Hong W; Wei X
MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
[TBL] [Abstract][Full Text] [Related]
26. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ
Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551
[TBL] [Abstract][Full Text] [Related]
27. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
28. Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.
Yang J; Hong W; Lei H; He C; Lei W; Zhou Y; Zhao T; Alu A; Ma X; Li J; Yang L; Wang Z; Wang W; Lu G; Shen G; Lu S; Wu G; Shi H; Wei X
Signal Transduct Target Ther; 2023 Jun; 8(1):252. PubMed ID: 37336889
[TBL] [Abstract][Full Text] [Related]
29. Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
Driouich JS; Bernadin O; Touret F; de Lamballerie X; Nougairède A
Antiviral Res; 2023 Jul; 215():105638. PubMed ID: 37207822
[TBL] [Abstract][Full Text] [Related]
30. Applications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV).
Nahhas AF; Webster TJ
Colloids Surf B Biointerfaces; 2024 Jan; 233():113638. PubMed ID: 37995630
[TBL] [Abstract][Full Text] [Related]
31. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
[TBL] [Abstract][Full Text] [Related]
33. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant.
Tamura T; Irie T; Deguchi S; Yajima H; Tsuda M; Nasser H; Mizuma K; Plianchaisuk A; Suzuki S; Uriu K; Begum MM; Shimizu R; Jonathan M; Suzuki R; Kondo T; Ito H; Kamiyama A; Yoshimatsu K; Shofa M; Hashimoto R; Anraku Y; Kimura KT; Kita S; Sasaki J; Sasaki-Tabata K; Maenaka K; Nao N; Wang L; Oda Y; ; Ikeda T; Saito A; Matsuno K; Ito J; Tanaka S; Sato K; Hashiguchi T; Takayama K; Fukuhara T
Nat Commun; 2024 Feb; 15(1):1176. PubMed ID: 38332154
[TBL] [Abstract][Full Text] [Related]
34. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.
Uraki R; Iida S; Halfmann PJ; Yamayoshi S; Hirata Y; Iwatsuki-Horimoto K; Kiso M; Ito M; Furusawa Y; Ueki H; Sakai-Tagawa Y; Kuroda M; Maemura T; Kim T; Mine S; Iwamoto N; Li R; Liu Y; Larson D; Fukushi S; Watanabe S; Maeda K; Wang Z; Ohmagari N; Theiler J; Fischer W; Korber B; Imai M; Suzuki T; Kawaoka Y
Nat Commun; 2023 Mar; 14(1):1620. PubMed ID: 36959194
[TBL] [Abstract][Full Text] [Related]
35. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
Li J; Mao H; Song W; Chen Y; Feng Y; Li J; Su L; Li X; Shi W; Wu Y; Huang C; Zhang Y; Chen K
J Med Virol; 2023 Dec; 95(12):e29306. PubMed ID: 38084772
[TBL] [Abstract][Full Text] [Related]
36. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
Parums DV
Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
[TBL] [Abstract][Full Text] [Related]
37. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
J Gen Virol; 2023 May; 104(5):. PubMed ID: 37167085
[TBL] [Abstract][Full Text] [Related]
38. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2.
Parums DV
Med Sci Monit; 2023 Sep; 29():e942244. PubMed ID: 37654205
[TBL] [Abstract][Full Text] [Related]
39. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding.
Jian F; Feng L; Yang S; Yu Y; Wang L; Song W; Yisimayi A; Chen X; Xu Y; Wang P; Yu L; Wang J; Liu L; Niu X; Wang J; Xiao T; An R; Wang Y; Gu Q; Shao F; Jin R; Shen Z; Wang Y; Wang X; Cao Y
PLoS Pathog; 2023 Dec; 19(12):e1011868. PubMed ID: 38117863
[TBL] [Abstract][Full Text] [Related]
40. Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection.
Jiang XL; Song XD; Shi C; Yang GJ; Wang XJ; Zhang YW; Wu J; Zhao LX; Zhang MZ; Wang MM; Chen RR; He XJ; Dai EH; Gao HX; Shen Y; Dong G; Wang YL; Ma MJ
Cell Rep; 2024 Jun; 43(7):114387. PubMed ID: 38896777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
